Mesh Bio raises $4.7m in Series A for health tech expansion with East Ventures

Elev8, Seed Capitals, and existing shareholders were also participants of this funding round.

Singapore-based health tech startup, Mesh Bio, has raised $4.7m (US$3.5m) in Series A financing led by East Ventures, a notable venture capital firm in Southeast Asia. 

Elev8, Seed Capitals, and existing shareholders also participated in this round. The funding will support Mesh Bio in providing its digital twin technologies to healthcare providers and expanding its solutions across Hong Kong and Southeast Asia, focusing on Indonesia and the Philippines. 

The investment comes after Mesh Bio obtained regulatory approval and initiated an implementation pilot with public health systems for its HealthVector Diabetes technology in Singapore. 

ALSO READ: GDMC secures $28.1m capital from Series A funding

The company's digital solutions aim to transform chronic disease management through predictive analytics, addressing unmet healthcare needs in Southeast Asia. 

Mesh Bio's DARA Health Intelligence Platform has been utilized by over 120 medical centres across Singapore, Malaysia, and Indonesia for preventive health screening. 

The funds will enable Mesh Bio to further advance its mission and contribute to the digital transformation of healthcare systems in the region.

($1.00 = US$0.75)